LOGIN  |  REGISTER
Viking Therapeutics
Amneal Pharmaceuticals

Rigel Pharmaceuticals to Participate in Upcoming September Investor Conferences

August 30, 2023 | Last Trade: US$17.05 0.56 3.40

SOUTH SAN FRANCISCO, Calif., Aug. 30, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, and Dean Schorno, the company's chief financial officer, will participate in the following investor conferences in September:

  • 2023 Wells Fargo Healthcare Conference, September 6-8, 2023, Boston, MA
    Raul Rodriguez will present a company overview on Wednesday, September 6th at 12:45 p.m. ET.

  • Citi's 18th Annual BioPharma Conference, September 6-7, 2023, Boston, MA
    Rigel management will participate in one-on-one meetings on Thursday, September 7th.

To access the live webcast of the Wells Fargo Healthcare Conference presentation, visit the Investor Relations section of the company's website at www.rigel.com. Please connect to Rigel's website prior to the start of the live webcast to allow for any software downloads.

About Rigel

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in South San Francisco, California. For more information on Rigel, the Company's marketed products and pipeline of potential products, visit www.rigel.com.

Investors & Media Contacts:  
Investors:
Rigel Pharmaceuticals, Inc.
650.624.1232
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Media:
David Rosen
Argot Partners
Phone: 212.600.1902
Email: This email address is being protected from spambots. You need JavaScript enabled to view it. 

 

Stock Quote

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page